The lymphoproliferative syndrome with large granular lymphocytes (LGL) is an heterogeneous disorder of unknown etiology. The analysis of T-cell receptor (TCR) genes rearrangements has shown that, in most cases, the disease is associated with clonal proliferation of CD8+CD57+ LGL. However, the putative neoplastic nature of these expansions remains questionable because clonal proliferations of CD8' cells have recently been found also in physiologic conditions. To obtain more precise information on the mechanisms responsible for LGL expansions, we decided to compare the molecular characteristics of TCRBV chains expressed by LGL with different phenotype and function, but derived from the same patients. To this end, we characterized, at the molecular level, the TCR repertoires of fractionated T-cell popula-HE LYMPHOPROLIFERATIVE disorder of large granular lymphocytes (LGL) has been widely studied, but several aspects of this disease, such as its etiology, remain obscure. Concerning the nature of LGL proliferations, a central question is whether they represent a neoplastic or a reactive disorder. Examination of T-cell receptor (TCR) gene rearrangements has shown that, in most patients, the disease is due to a clonal proliferation'"; however, polyclonal patterns of TCR rearrangements have also been documented.'"'
The lymphoproliferative syndrome with large granular lymphocytes (LGL) is an heterogeneous disorder of unknown etiology. The analysis of T-cell receptor (TCR) genes rearrangements has shown that, in most cases, the disease is associated with clonal proliferation of CD8+CD57+ LGL. However, the putative neoplastic nature of these expansions remains questionable because clonal proliferations of CD8' cells have recently been found also in physiologic conditions. To obtain more precise information on the mechanisms responsible for LGL expansions, we decided to compare the molecular characteristics of TCRBV chains expressed by LGL with different phenotype and function, but derived from the same patients. To this end, we characterized, at the molecular level, the TCR repertoires of fractionated T-cell popula-HE LYMPHOPROLIFERATIVE disorder of large granular lymphocytes (LGL) has been widely studied, but several aspects of this disease, such as its etiology, remain obscure. Concerning the nature of LGL proliferations, a central question is whether they represent a neoplastic or a reactive disorder. Examination of T-cell receptor (TCR) gene rearrangements has shown that, in most patients, the disease is due to a clonal proliferation'"; however, polyclonal patterns of TCR rearrangements have also been documented.'"'
Although the identification of clonal expansions has initially been taken as evidence of malignancy,' it is now evident that this is not the case, because mono/oligoclonal T cells have been detected in normal individ~als""~ and in several human Thus, the identification of clonal expansions does not necessarily imply the presence of neoplastic transformations and does not exclude the possibility of clonal selection caused by antigenic pressures. Indeed, Kasten-Sport& et alZ3 have reported a case of LGL proliferation characterized by the monoclonal expansion of one TCRBV segment, associated to a common TCRAV chain joined in frame with different TCRAJ segments. Furthermore, we have recently reported a case of LGL proliferation in which the expanded cells were characterized by the expression of few TCRBV segments that shared amino acid motifs in their CDR3 region^.'^ Although these data question the malignant nature of LGL proliferations, they also stress how the mere analysis of TCR gene rearrangements by the conventional method may not be appropriate for clearly defining the driving forces that preside over these T-cell proliferations.
Immunologic analysis showed that most LGL expansions show mature T-cell phenotype; in the great majority of cases, CD3+ LGL express the CD8 and lack the CD4 molecule, but LGL proliferations characterized by rare CD3+CD4+CD8-, CD3+CD4+CD8+, or CD3+CD4-CD8-phenotypes have also been rep~rted.'.~.'~ Less frequently, LGL expansions display a non-T-cell phenotype and a heterogeneous pattern of expression for CD2, CD8, CD56, and CD57 antigen^.^.'^.'' Considering the different functions and recognition pat- LGL. Our resutts show that the dominant TCRBV chains expressed by the dimrent CD4+ and CD4-LGL populations were strictly oligoclonal. However, the molecular characteristics of the dominant V-DJ rearrangements also imply that the selection of these clones was not due to a neoplastic event. Rather, our data suggest that these particular LGL Proliferations can be ascribed to a chronic T-cell-mediated immune response that involves recognition by the engaged TCR of antigens that are not necessarily presented to immune system in the classical major histocompatibility complex-restricted pathway. terns of CD4' and CD8' T-cell subsets, the study of the mechanisms responsible for LGL expansions could potentially benefit from the availability of CD4+ and CD8+ LGL derived from the same patient. So far, only one of such cases has been studied in detail, and it was found that the CD4+ and CD8+ LGL components were both clonal, but showed different patterns of TCRGD rearrangements.2 ' We report here the fine molecular analysis of the TCRBV segments of fractionated cells of patients with increased numbers of LGL and with concurrent expansion of CD8+CD57+ and of CD4+CD57+ LGL.
Collectively, our data not only question the malignant nature of these LGL proliferations, but rather they support a model of clonal expansion consequent to a strong antigenic pressure acting on both CD4 and CD8 T-cell subsets. transient nature of this proliferation was shown by the progressive decline of both lymphocytosis and LGL in sequential blood samples (samples P1, P2, and P3), which were obtained at 1,4, and 9 months after the seroconversion. According to the Centers for Disease Control (CDC) criteria for HIV-related disorders, he is classified as group A2. REFE (group A1 of CDC) is also a male intravenous drug user who became HIV-seropositive in 1986 and who had suffered from posttraumatic splenectomy in 1991. The lymphocytosis and the increased presence of circulating LGL were first diagnosed in the beginning of 1994 and were still present in the blood samples RI, R2, R3, and R4, which were taken at regular intervals since October 1994. SAIN is an HIV' patient (group B2 of CDC) who was regularly monitored since the middle of 1994, when he showed symptoms of an acute HIV infection and became seropositive. The increase in the number of circulating LGL was occasionally found in sample SI, which was taken more that 1 year after the seroconversion and is still present (sample S2). Samples I1 and I2 were from patient IOPU, a non-HIV female with granulocytopenia and with a longlasting presence of circulating LGL. This patient had no sign of splenomegaly, lymphoadenopathy, or hepatomegaly and has remained relatively asymptomatic until now. Routine TCR gene analysis, which was performed by conventional Southern blot analysis using "P-DNA probes, did not provide clear and definitive results; therefore, this patient was sent to us for a more detailed characterization of TCRBV repertoire.
Patients PGSC, SAIN, REFE, and IOPU were negative for antibodies against human T-cell leukemia virus I , whereas HIV + individuals were IgG-specific for cytomegalovirus (CMV) and EpsteinBarr virus (EBV).
We also analyzed, as controls, several individuals with a normal number of circulating LGL: 9 HIV+ patients, belonging to the same groups of CDC classification of PGSC, SAIN, and REFE; 3 HIVindividuals who underwent a posttraumatic splenectomy; 4 patients convalescing from infections by human herpes virus 2 (HHV2), CMV, hepatitis B virus (HBV), and EBV; and 7 normal healthy donors.
Lymphocyte subpopulations' preparation. After Ficoll-Hypaque gradient centrifugation, the different lymphocyte subpopulations were prepared by using magnetic microspherical beads coated with specific monoclonal antibodies (MoAbs; Dynabeads M-450 CD4 and Dynabeads M-450 rat antimouse IgM; Dynal, Oslo, Norway) and DETACHaBEAD, following the manufacturer's instructions. CD4+ and CD4-subsets were prepared from all control samples, from samples P1 and SI of patients PGSC and SAIN, and from samples R1 and R2 of patient REFE, whereas four different subpopulations (CD4'CD57+, CD4+CD57-, CD4-CD57+, and CD4-CD57-) were prepared from samples P2, R3, and I I. Because of the scarce amount of available biologic material and the low number of CD4 lymphocytes, CD4-lymphocytes from sample S1 were separated only in two subsets (CD4-CD57' and CD4-CD57-l The morphology of LGL and the purity of cell subsets, which was analyzed by cytofluorimetry, were studied after each step of the preparations. Morphologic analysis for evaluation of LGL was performed on May-Griinwald Giemsa-stained cytospin; at light microscopy, LGL were similar in all cases, being medium size cells with moderate to abundant pale blue cytoplasm containing azurophilic granules.
Cytojuorimetric analysis. The expression of cell surface antigens was studied with direct one-color or two-color analysis using a panel of purified, phycoerythrin (PE)-or fluorescein isothiocyanate (F1TC)-conjugated MoAbs. Anti-CD3, anti-CD4, anti-CD8, anti-CD56, anti-CD57, anti-CD19, anti-HLA-DR, anti-TCRAB, anti-CD45RA, and anti-CD45RO MoAbs were obtained from Becton Dickinson (Mountain View, CA), the anti-TCRGD was from T-cell Sciences (Cambridge, MA), and the anti-CD16 was from Immunotech (Marseille, France). Cells were analyzed using a flow cytometer (FACScan; Becton Dickinson, Erembodegem-aalst, Belgium) equipped with an argon-ion laser. Cells were stained according to the manufacturer's instructions. Briefly, 3 X 10 cells were incubated for 30 minutes at 4°C with PE-and FITC-conjugated MoAbs. The flow cytometer was gated to include only viable cells. A total of 1 X IO4 cells was accumulated for histograms using logarithmic amplification of fluorescence intensity.
Prepuration of RNA, complementav DNA (cDNA) synthesis, and ampl$cation of cDNA by polymerase chain reaction (PCR). Total RNA was prepared by the guanidinium thiocyanate-phenol-chloroform method from all lymphocyte subpopulations. One microgram of total RNA was used to synthesize the first strand of the TCRB chain-specific cDNA using the RiboClone cDNA Synthesis System (Promega Corp, Madison, WI) and a primer specific for TCRBCI and TCRBC2 genes (@DNA: 5' GGG CTG CTC CTT GAG GGG CTG CGG 3'). cDNA was then subjected to enzymatic amplification using a second human TCRBC primer @AI: 5' CCC ACT GTG CAC CTC C'M CC 3') and a TCRBV degenerated primer [Vpd: G)(AT) CA 3'1, which was designed to amplify TCRB chain rearrangements containing virtually all the known human TCRBV genes." The 40 cycles of PCR were performed under the following conditions: denaturation at 93°C for I minute, annealing at 52°C for 1 minute, and extension at 72°C for 1 minute; the last cycle extension was performed at 72°C for 7 minutes. The specificity of the total amplified products, which was analyzed using a colorimetric method and biotinylated TCRBV-specific probes, and the relative percentage of expression of each TCRBV segment was performed as previously described.'" Subsequently, the TCRBV chains of interest were amplified by PCR using TCRBV-specific family primers (TCRBV2: 5' TCA TCA ACC ATG CAA GCC TGA CCT 3'; TCRBV3: 5' GTC TCT AGA GAG AAG AAG GAG CGC 3'; TCRBV6: S' AGG CCT GAG GGA TCC GTC TC 3'; TCRBVI 1: 5' TCA ACA GTC TCC AGA ATA AGG ACG 3'; and TCRBVIS: 5' AGT GTC TCT CGA CAG GCA CAG GCT 3') and a TCRBC oligonucleotide (BAI).
Cloning and sequencing of PCR products. The PCR products were purified by cutting the band with the expected size from NuSieve GTG low melting agarose 2.5% gel (FMC BioProducts, Rockland, ME) and eluting the melted gel through an ion-exchange resin column (Qiagen tip 5; Qiagen Inc, Chatsworth, CA). Purified DNA fragments were ligated to pCR I1 vector. Plasmids were grown in 1NVaF"modified competent Escherichia coli cells in LB agar plates, and single plaques were picked up and expanded according to the manufacturer's instructions (TA cloning kit; Invitrogen Corp, San Diego, CA). To verify the presence of the correct insert, recombinant plaques were tested by PCR with the above described TCRBVspecific family primers and with 2 primers specific for the TCRBC segment (the antisense PA1 primer and the sense oligonucleotide Col: 5' GTC GCT GTG TTT GAG CCA TCA GAA 3'). Plasmid DNA from TCRBV-positive plaques was sequenced with Automated Laser Fluorescent A.L.F. DNA Sequencer (Pharmacia LKB, Uppsala, Sweden) using AutoRead Sequencing Kit (Pharmacia). Sequences were compared with published data relative to TCRBV, TCRBD, TCRBJ, and TCRBC segments.""'
5' ACG TGA ATT CT(GT) T(ACT)(CT) TGG TA(CT) (AC)(A-

RESULTS
Churucterizution of the patients.
The morphologic and phenotypic characterization of the patients enrolled in this study is shown in Table 1 suffered from a classic long-lasting LGL proliferation (lymphocytes >4,OOO/pL and LGL >2,0oO/pL). The HIV-patient IOPU, who showed neutropenia, was not affected by a classical lymphoproliferative syndrome because the LGL number was less than 2,oOO/pL.* However, it must also be noted that clonal diseases have been documented in patients with absolute LGL count as low as 700/pL.' As shown in Table 1 , lymphocytes coexpressing the CD8 and CD57 markers were increased in the four patients and, unexpectedly, we also detected a small percentage of CD4 cells that expressed the CD57 molecule. The vast majority of these patients' T lymphocytes expressed TCRAB molecules and less than 6% of the cells were TCRGD+. The first analysis of the TCRBV repertoire was performed 2 g on a pure preparation of CD4+ and CD4-cells prepared ' ! g from healthy donors, virus-infected individuals, and HIV-S r .
5 5 subjects (Fig 1) or obtained from samples P1, S1, and R1 g < respectively (Fig 2) . In sample PI, the TCRBV3 chain was x % H 2 preferentially expressed by CD4-cells (Fig 2, top panel) , .-W which should comprise the majority of the LGL population.
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The sequencing of these TCRBV3 transcripts showed an compatible with the transient emergence of an antigen-reac-5 P tive LGL population, consequent to a primary HIV infection.
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The analysis of TCRBV usage performed in sample S1
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showed an increase of CD4-lymphocytes bearing the : : :: TCRBVll segment (Fig 2, middle panel) . This feature was Table 1 ) derived from patients PGSC, SAIN, and R E F E , .- In sample R I , on the other hand, there was not a dominant TCRBV chain among the CD4" cells, as found in samples PI and SI and as is usually observed in classical CD8' LGL proliferations'.''; however, there was a preferential expansion of TCRBVIS segment in the CD4' T-cell subset (Fig  2, bottom panel) . This feature was confirmed with a second sample (R2) obtained 4 months later. In this sample, we also detected the dominant expression of TCRBV3 transcripts in the CD4' cell population (data not shown). To define the nature of the TCRBV I S' cell increase observed in sample R l , we sequenced several of these transcripts from CD4' and CD4-subpopulations. An identical dominant clone bearing TCRBJ2SI region was identified in both T-cell preparations; furthermore, the first 6 amino acids of the CDR3 region of the other two clones found among CD4' cells were identical to those contained in the dominant clone, but joined in frame with TCRBJ2S2 segment, whereas another clone contained only I amino acid replacement (Arg + Gly). LGL.
The unusual TCRBV profile of CD4' lymphocytes and the increased presence of CD4'CDS7' cells observed in patient REFE in comparison to controls (Table l) , but, especially, the identical clones found in CD4' and CD4-populations, prompted us to better characterize the TCRBV usage in more selected T-cell subsets prepared from a third blood sample obtained from the same patient 4 months later (sample R3). The purified CD4' and CD4" cells were therefore further separated on the basis of their cell surface expression of the CD57 molecule. The same T-cell populations were also isolated from a second sample obtained from patient PGSC (P2) and used as control material. Detailed two-color immunophenotyping was undertaken using a Row cytometer to determine the purity of each cell specimen. The CD4' preparation of sample R3 contained, after beads detachment, 4.4% of contaminating CD8' cells. whereas we detected only 0.3% of CD4' cells in the CD4-subset. The CD4-preparation of sample P2 contained 59% of contaminating CD4' cells, whereas 1.2% of cells bearing the CD8 marker was detected in CD4' lymphocyte preparation. Technical impairments associated to the impossibility of performing a second TCRBV expression by CD4+ (M) and CD4-(B) cell subpopulations prepared from samples P1, S1, and R1 obtained from patients PGSC, SAIN, and REFE, respectively. The data are expressed as the percentage of the colorimetric signal obtained with the individual TCRBVspecific probes. The junctional amino acids ofTCRBV3, TCRBV11, and TCRBV15 sequences, obtained from the indicated T lymphocyte subpopulations, were deduced from nucleotide sequences and displayed as the standard one-letter code. Only the last 7 amino acids of the TCRBV segments and the first 5' amino acids of TCRBJ chains are shown. n., number of clones sequenced; ", the indicated TCRBVll clones are sequenced from different blood samples obtained a t 1.5,6, and 12 months after the seroconversion.
beads detachment allowed the assessment of cell purity only irrelevant, whereas there was a slight contamination in the in the CD4TD57-and CD4-CD57-cell subsets of both CD4-CD57-cell prepared from sample P2. Table 3 shows patients. As shown in Table 2 , the level of cellular contamithat, in both patients, the typical morphology of LGL was nation in the two populations obtained from sample R3 was preferentially observed in the CD4-lymphocyte prepara- tions. However, surprisingly, we also observed that 25% of CD4' cells prepared from sample R3 had LGL morphology. Because LGL were not detected in the CD4+CD57-preparation of this sample, we estimated that the vast majority of these CD4+
LGL also express the CD57 marker. The data from one of two independent experiments obtained with separated T-cell subsets of sample R3 are shown in Fig 3. In both experiments, we repeatedly observed that the TCRBV3 and TCRBV15 chains were dominantly expressed by CD4+CD57+ cells, whereas in the other T-cell subsets we could not detect the presence of prevalent TCRBV transcripts. The same analysis performed with samples P2 and S 1, on the other hand, showed that, as expected, the dominant TCRBV3 and TCRBV11 chains were preferentially expressed by cells with the CD4-CD57' phenotype (data not shown). To obtain more detailed information on the nature of the increase of TCRBV3+ and TCRBV15+ cells observed in sample R3, we sequenced several of these transcripts from the different T-cell subpopulations. Also in this case, the rearrangements of the TCRBVl5 chain were found to be extremely restricted and similar in the T-cell preparations studied. These results are therefore compatible with a strong antigenic pressure acting on the different T-cell subsets responsible for the selection of clones with a conserved CDR3 region. The data relative to the analysis of TCRBV3 sequences showed the existence of a dominant clone in the CD4+CD57+ T-cell subset and of a more heterogeneous pattern of rearrangements in the other cell populations. Thus, contrary to the case of TCRBV15, the expansion of the prevalent TCRBV3 segment is probably due to selective pressures acting preferentially on CD4+CD57+ lymphocytes. To verify whether the molecular characteristics of the TCRBV repertoire of REFE were specifically linked to HIV infection, we studied the TCRBV usage of a non-HIV subject who also showed an increased presence of circulating LGL and an abnormal expansion of CD4+CD57+ cells. The purity of T-cell subsets and the distribution of LGL among the different cell populations are shown in Tables 2 and 3 , respectively. The TCRBV repertoire analysis showed that there was also in this case a preferential usage of two TCRBV segments (TCRBV2 and TCRBV6) in the CD4+CD57+ subpopulation (Fig 4) . The sequencing of the dominant TCRBV6 chains showed a clear selection of two identical clones in both CD4+CD57+ and CD4-CD57+ Tcell subsets, whereas the pattern of rearrangement of this TCRBV segment was much more heterogeneous in the CD4+CD57-T-cell subpopulation.
The analysis of the TCRBV2 segment also defined the presence of oligoclonal expansions in the CD4+CD57+ and CD4-CD57' T-cell subsets, but in this case, as already observed with the analysis of patient REFE, the rearrangements detected in the two subpopulations were extremely similar, but not identical. It is interesting to note that one of the dominant clones in the CD4+CD57+ T-cell subset, bearing the TCRBJ2S7 region, contained a CDR3 sequence that differed from the sequence of the prevalent clone detected in the CD4CD57' subpopulation by 1 amino acid replacement (Ala -+ Gly) and 1 amino acid addition (Pro). Furthermore, two of The For the dominant clones detected among the CD4-CD57' subset contained the same Gly-Pro-Gly motif in the CDR3 region, suggesting that these clones, in this case, also have been selected by antigenic pressures. As in the case of TCRBV6 chain, the pattern of rearrangement of TCRBV2 segments in the CD4TD57-subpopulation was completely unrestricted.
TCRBVlS SEGMENTS
A final observation that emerged from the analysis of all the sequences of patient IOPU is the prevalent usage of TCRBJISS in the dominant clones.
DISCUSSION
It is now recognized that CD3' LGL are clonally derived from their normal counterpart, but the nature of the pressure responsible for the expansion of these cells remains unclear. Although initially the detection of TCR clonal rearrangement in LGL was taken as a proof of neoplastic transformation, it is now clear that this extrapolation is untenable because mono/oligoclonal T-cell populations have been detected within particular T-cell populations both in pathologic and physiologic conditions."." Thus, an alternative approach to study the nature of these LGL proliferations is the comparison of the molecular characteristics of the TCR expressed by LGL with different phenotype and function, but derived from the same patient.
In the vast majority of cases, CD3' LGL express the CD8 and lack the CD4 surface antigen,'.s but LGL expansions characterized by CD3TD8-CD4' phenotype have also been reported??' Most of LGL bears also the CD57 mole~ule'~ thought to correlate with in vivo-activated cytotoxic T lymphocytes. We were surprised, therefore, when, in the course of a study of patients with LGL proliferations, we identified an HIV' subject (REFE) in whom LGL proliferation involved both the CD4 and CD8 cell subsets. Although the majority of LGL was found in the CD4-preparation, 25% of purified CD4' cells had the typical LGL morphology and 9% of them also expressed the CD57 marker. Because LGL were not observed in the CD4TD57-T-cell subset, we estimated that about 77% of the CD4TD57' cell preparation was composed of LGL. The observed increase of CD4TD57' is apparently not related to the splenectomy because the splenectomized HIV-subjects used as controls did not show an expansion of these cells. Thus, the availability of patient REFE offered us a unique opportunity to compare the TCR repertoire of LGL derived from CD4'CD57' and CD4TD57' cells of the same patient. Our data show that the dominant TCRBV chains expressed by the LGLenriched CD4TD57' population were strictly oligoclonal. In the case of the TCRBVIS chain, we detected only one dominant V-D-J rearrangement, whereas the sequences of the TCRBV3 segment suggested the existence of 1 predominant clone, bearing the TCRBJ 1S2 region, and 2 other minor clones, joined in frame with TCRBJ2S6 and TCRBJ2S7. It was surprising to observe that the TCRBVIS segments, expressed by the CD4-CD57' and the CD4TD57-subsets, contained two types of rearrangements. One was identical to that detected in the CD4+CD57+ population, whereas, in the other one, the first 6 amino acids of the CDR3 region were identical to those observed in the dominant clone, but were joined in frame to a different TCRBJ segment. Because such a feature cannot be casual, it is unlikely that the selective pressure can be ascribed to sequential transforming events acting on a given cell independently from its TCR antigen-specificity, as it occurs in the case of neoplastic transformation. Because the CDR3 loop of TCRBV chains is formed by the joining of the V-D-J segments and interacts predominantly with determinants on the bound peptide of the antigedmajor histocompatability complex (MHC);" our data rather suggest that the selection of the clones is due to a strong antigen stimulation. In support of this hypothesis, it is worth mentioning that cytotoxic T clones containing the same N-D-N region, but joined in frame with different TCRBJ regions, have been shown to recognize the same HIV-derived antigens?' However, it should be stressed that the clonal expansions observed in our patients are quite different from those found in patients with LGL leukemia, in whom the dominant clone constitutes a large portion of the circulatory cells and is easily identifiable by conventional methods such as Southern blotting.' Neoplastic T cells can also be identified by PCR as a dominant TCRBV chain, with other segments being very low or absent (Davey et al' and Sottini et al, manuscript in press). Therefore, the clonal populations identified by PCR in normal individuals""' and those found in this study probably represent major clonal expansions within a specific T-cell subpopulation, but minor expansions if considered in the context of the totality of all circulating lymphocytes.
The almost identity of the receptor ligand expressed by CD4' and CD4-lymphocytes that are theoretically deputed provided formal evidence that, in contrast to recognition of MHC-bound peptide antigens by most T cells, some human T lymphocytes can recognize naturally occurring small nonpeptidic antigens. Although in this study the involved cells expressed TCRGD chains, it cannot be excluded that TCRAB cells, such as those detected in the patient REF%, can also be implicated in the recognition of nonproteic antigens in an MHC unrestricted way. Interestingly, these lymphocytes that express an unusually restricted TCRBV repertoire are reminiscent of mouse CD4+CD8-NK1.1+ T cells, a subset of lymphocytes that, contrary to CD4+CD8-NK1 .l-TCRAB' population, is HLA class I re~tricted.4~ Furthermore, the morphology of these mouse T cells," with their granule contents, is associated with the new family of mouse lymphocytes to human LGL. Finally, we stress that the TCRBVll chain (clonally expressed by CD4+ cells of patient SAIN) is extremely homologous to the mouse TCRBV8 segment, which is preferentially expressed by mouse NK1.1+ lymph0cytes.4~ These similarities suggest that human CD4+CD57+ LGL could be the equivalent of mouse NK1.l T cells and that they could play an important regulatory role in immune responses.
Evidence of antigenic selection of LGL was also obtained with the analysis of patient IOPU, in whom we observed that both the CD4+CD57+ and CD4-CD57+ T-cell subsets contained dominant TCRBV segments with closely resembling V-D-J rearrangements. It is remarkable that, in this sample, the CD4+CD57+ subset, which was also strongly oligoclonal, contained only 30% of LGL. Thus, it is likely that oligoclonality is a general feature of CD57+ cells independently by their LGL morphology. This hypothesis is further supported by the fact that, in all of the patients studied, the C D 5 F subset was always found to be mono/oligoclonal independent by CD4 and CD8 phenotype and by the number of cells with the LGL morphology present. Therefore, it is tempting to conclude that the widely reported mono/oligoclonality of LGL does not reflect an intrinsic and specific feature of this particular cell type, but is rather a consequence of the fact that, in the majority of cases, LGL belong to the pool of CD57+ cells. The fact that reactive LGL, such as those observed in the patient PGSC, were less restricted than those of the other patients, could also imply that LGL proliferations result from the abnormal selection of particular clones after the physiologic expansion of this type of cells consequent to viral or bacterial infections.
Concerning the mechanisms responsible for the expansion of CD57+ cells, it should be noted that the increase of CD4-CD57+ lymphocytes is generally detected in clinical conditions involving strong antigenic pressure acting on CD8 cells, such as during viral or after bone marrow tran~plantation.~' Moreover, mono/oligoclonal expansions of CD57+ lymphocytes have been reported in patients with rheumatoid arthritis:' in physiologic condition^,'^ and in aging.52 Therefore, it is likely that, as suggested by Gorochov et a1: ' permanent activation of T lymphocytes may induce the cell surface expression of the CD57 molecule on CD8 cells and, possibly, also on CD4 lymphocytes.
In conclusion, the possibility to study the molecular characteristics of the TCRBV segments in CD4+CD57+ and CD4-CD57+ populations obtained from the same patients has allowed us to provide new evidence suggesting that LGL expansion can represent a chronic T-cell-mediated immune response that involves recognition by the engaged TCR of antigens that are not necessarily presented to the immune system in an MHC-restricted pathway. Furthermore, our results question the validity of assessing the mono/oligoclonality of the TCR as a mode of defining the possible association between LGL and neoplastic transformation.
